Literature DB >> 10931193

Synthetic substrates and inhibitors of beta-poly(L-malate)-hydrolase (polymalatase).

B Gasslmaier1, C M Krell, D Seebach, E Holler.   

Abstract

Polymalatase from Physarum polycephalum calalysed the hydrolysis of beta-poly[L-malate] and of the synthetic compounds beta-di(L-malate), beta-tetra(L-malate), beta-tetra(L-malate) beta-propylester, and L-malate beta-methylester. Cyclic beta-tri(L-malate), cyclic beta-tetra(L-malate), and D-malate beta-methylester were not cleaved, but were competitive inhibitors. The O-terminal acetate of beta-tetra(L-malate) was neither a substrate nor an inhibitor. L-Malate was liberated; the Km, Ki and Vmax values were measured. The appearance of comparable amounts of beta-tri(L-malate), and beta-di(L-malate) during the cleavage of beta-tetra(L-malate) indicated a distributive mechanism for small substrates. The accumulation of a series of oligomers, peaking with the 11-mer and 12-mer in the absence of higher intermediates, indicated that the depolymerization of beta-poly(L-malate) was processive. The results indicate that beta-poly(L-malate) is anchored at its OH-terminus by the highly specific binding of the penultimate malyl residue. The malyl moieties beyond 12 residues downstream from the OH-terminus extend into a diffuse second, electrostatic binding site. The catalytic site joins the first binding site, accounting for the cleavage of the polymer into malate residues. It is proposed that the enzyme does not dissociate from beta-poly(L-malate) during hydrolysis, when both sites are filled with the polymer. When only the first binding site is filled, the reaction partitions at each oligomer between hydrolysis and dissociation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10931193     DOI: 10.1046/j.1432-1327.2000.01573.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  11 in total

1.  Nanoconjugate Platforms Development Based in Poly(β,L-Malic Acid) Methyl Esters for Tumor Drug Delivery.

Authors:  José Portilla-Arias; Rameshwar Patil; Jinwei Hu; Hui Ding; Keith L Black; Montserrat García-Alvarez; Sebastián Muñoz-Guerra; Julia Y Ljubimova; Eggehard Holler
Journal:  J Nanotechnol       Date:  2010

Review 2.  Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Authors:  Julia Y Ljubimova; Tao Sun; Leila Mashouf; Alexander V Ljubimov; Liron L Israel; Vladimir A Ljubimov; Vida Falahatian; Eggehard Holler
Journal:  Adv Drug Deliv Rev       Date:  2017-06-10       Impact factor: 15.470

3.  Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity.

Authors:  Satoshi Inoue; Hui Ding; Jose Portilla-Arias; Jinwei Hu; Bindu Konda; Manabu Fujita; Andres Espinoza; Sonal Suhane; Marisa Riley; Marcus Gates; Rameshwar Patil; Manuel L Penichet; Alexander V Ljubimov; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

4.  Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.

Authors:  Hui Ding; Gustavo Helguera; José A Rodríguez; Janet Markman; Rosendo Luria-Pérez; Pallavi Gangalum; Jose Portilla-Arias; Satoshi Inoue; Tracy R Daniels-Wells; Keith Black; Eggehard Holler; Manuel L Penichet; Julia Y Ljubimova
Journal:  J Control Release       Date:  2013-06-12       Impact factor: 9.776

5.  Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid).

Authors:  Manabu Fujita; Bong-Seop Lee; Natalya M Khazenzon; Manuel L Penichet; Kolja A Wawrowsky; Rameshwar Patil; Hui Ding; Eggehard Holler; Keith L Black; Julia Y Ljubimova
Journal:  J Control Release       Date:  2007-06-05       Impact factor: 9.776

6.  Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Authors:  Satoshi Inoue; Rameshwar Patil; Jose Portilla-Arias; Hui Ding; Bindu Konda; Andres Espinoza; Dmitriy Mongayt; Janet L Markman; Adam Elramsisy; H Westley Phillips; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

Review 7.  Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy?

Authors:  Babak Kateb; Katherine Chiu; Keith L Black; Vicky Yamamoto; Bhavraj Khalsa; Julia Y Ljubimova; Hui Ding; Rameshwar Patil; Jose Antonio Portilla-Arias; Mike Modo; David F Moore; Keyvan Farahani; Michael S Okun; Neal Prakash; Josh Neman; Daniel Ahdoot; Warren Grundfest; Shouleh Nikzad; John D Heiss
Journal:  Neuroimage       Date:  2010-02-10       Impact factor: 7.400

Review 8.  Biosynthetic Polymalic Acid as a Delivery Nanoplatform for Translational Cancer Medicine.

Authors:  Jianguo Zhang; Deyu Chen; Guoxin Liang; Wenrong Xu; Zhimin Tao
Journal:  Trends Biochem Sci       Date:  2020-10-22       Impact factor: 13.807

Review 9.  Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic.

Authors:  Vladimir A Ljubimov; Arshia Ramesh; Saya Davani; Moise Danielpour; Joshua J Breunig; Keith L Black
Journal:  Adv Drug Deliv Rev       Date:  2021-11-20       Impact factor: 17.873

Review 10.  Application of nanoparticles on diagnosis and therapy in gliomas.

Authors:  Norma Y Hernández-Pedro; Edgar Rangel-López; Roxana Magaña-Maldonado; Verónica Pérez de la Cruz; Abel Santamaría del Angel; Benjamín Pineda; Julio Sotelo
Journal:  Biomed Res Int       Date:  2013-04-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.